Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAndrew, N.-
dc.contributor.authorKearney, D.-
dc.contributor.authorSelva-Nayagam, D.-
dc.identifier.citationEye, 2013; 27(4):561-563-
dc.description.abstractPURPOSE The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH). PATIENTS AND METHOD Retrospective, single-centre, interventional case series. RESULTS Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection. CONCLUSION Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.-
dc.description.statementofresponsibilityNH Andrew, D Kearney and D Selva-
dc.publisherNature Publishing Group-
dc.rights© 2013 Macmillan Publishers Limited All rights reserved-
dc.subjectreactive lymphoid hyperplasia-
dc.subjectlymphoproliferative disorders-
dc.subjectdrug therapy-
dc.subjectorbital disease-
dc.titleIntraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia-
dc.typeJournal article-
dc.identifier.orcidSelva-Nayagam, D. [0000-0002-2169-5417]-
Appears in Collections:Aurora harvest 4
Opthalmology & Visual Sciences publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.